Jul 21, 2022

Featuring an interview with Professor Juan Valle, including the following topics:

• Immunotherapy for patients with biliary tract cancers (BTCs) (0:00)
• Etiology and presentation of and recent advances in the management of cholangiocarcinoma (4:18)
• Targeting FGFR alterations in cholangiocarcinoma and other BTCs (12:47)
• Spectrum and management of toxicities associated with FGFR inhibitors (19:33)
• Targeting driver mutations beyond FGFR (28:16)
• Case: A man in his early 60s with intrahepatic cholangiocarcinoma, an FGFR2 fusion and an IDH1 R132C mutation (35:53)
• Case: A woman in her early 60s with intrahepatic cholangiocarcinoma and an IDH1 mutation that did not respond to third-line ivosidenib (41:49)
• Case: A woman in her early 60s with gallbladder cancer who received first-line chemotherapy with pembrolizumab (46:15)

CME information and select publications